134 related articles for article (PubMed ID: 25869319)
41. Quantitative structure-activity relationships and docking studies of calcitonin gene-related peptide antagonists.
Kyani A; Mehrabian M; Jenssen H
Chem Biol Drug Des; 2012 Feb; 79(2):166-76. PubMed ID: 21974743
[TBL] [Abstract][Full Text] [Related]
42. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.
Degnan AP; Chaturvedula PV; Conway CM; Cook DA; Davis CD; Denton R; Han X; Macci R; Mathias NR; Moench P; Pin SS; Ren SX; Schartman R; Signor LJ; Thalody G; Widmann KA; Xu C; Macor JE; Dubowchik GM
J Med Chem; 2008 Aug; 51(16):4858-61. PubMed ID: 18665579
[TBL] [Abstract][Full Text] [Related]
43. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
44. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
Gupta S; Villalón CM
Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
[TBL] [Abstract][Full Text] [Related]
45. Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine.
Nichols PL; Brand J; Briggs M; D'Angeli M; Farge J; Garland SL; Goldsmith P; Hutchings R; Kilford I; Li HY; MacPherson D; Nimmo F; Sanderson FD; Sehmi S; Shuker N; Skidmore J; Stott M; Sweeting J; Tajuddin H; Takle AK; Trani G; Wall ID; Ward R; Wilson DM; Witty D
Bioorg Med Chem Lett; 2010 Feb; 20(4):1368-72. PubMed ID: 20097071
[TBL] [Abstract][Full Text] [Related]
46. CGRP antagonists: unravelling the role of CGRP in migraine.
Doods H; Arndt K; Rudolf K; Just S
Trends Pharmacol Sci; 2007 Nov; 28(11):580-7. PubMed ID: 17963849
[TBL] [Abstract][Full Text] [Related]
47. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
Cady RK; Vause CV; Ho TW; Bigal ME; Durham PL
Headache; 2009 Oct; 49(9):1258-66. PubMed ID: 19788468
[TBL] [Abstract][Full Text] [Related]
48. Binding profile of a selective calcitonin gene-related peptide (CGRP) receptor antagonist ligand, [125I-Tyr]hCGRP8-37, in rat brain and peripheral tissues.
Van Rossum D; Ménard DP; Fournier A; St-Pierre S; Quirion R
J Pharmacol Exp Ther; 1994 May; 269(2):846-53. PubMed ID: 8182554
[TBL] [Abstract][Full Text] [Related]
49. Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines.
Iftikhar H; Ahmad I; Gan SH; Shaik MM; Iftikhar N; Nawaz MS; Greig NH; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(7):1130-9. PubMed ID: 25230231
[TBL] [Abstract][Full Text] [Related]
50. Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability.
Degnan AP; Conway CM; Dalterio RA; Macci R; Mercer SE; Schartman R; Xu C; Dubowchik GM; Macor JE
Bioorg Med Chem Lett; 2009 Jul; 19(13):3555-8. PubMed ID: 19467597
[TBL] [Abstract][Full Text] [Related]
51. Impact of Food Components on in vitro Calcitonin Gene-Related Peptide Secretion-A Potential Mechanism for Dietary Influence on Migraine.
Slavin M; Bourguignon J; Jackson K; Orciga MA
Nutrients; 2016 Jul; 8(7):. PubMed ID: 27376323
[TBL] [Abstract][Full Text] [Related]
52. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
Tepper SJ; Cleves C
Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
[TBL] [Abstract][Full Text] [Related]
53. Functional calcitonin gene-related peptide subtype 2 receptors in porcine coronary arteries are identified as calcitonin gene-related peptide subtype 1 receptors by radioligand binding and reverse transcription-polymerase chain reaction.
Rorabaugh BR; Scofield MA; Smith DD; Jeffries WB; Abel PW
J Pharmacol Exp Ther; 2001 Dec; 299(3):1086-94. PubMed ID: 11714898
[TBL] [Abstract][Full Text] [Related]
54. Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.
Burgey CS; Stump CA; Nguyen DN; Deng JZ; Quigley AG; Norton BR; Bell IM; Mosser SD; Salvatore CA; Rutledge RZ; Kane SA; Koblan KS; Vacca JP; Graham SL; Williams TM
Bioorg Med Chem Lett; 2006 Oct; 16(19):5052-6. PubMed ID: 16889959
[TBL] [Abstract][Full Text] [Related]
55. To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations.
Leung L; Liao S; Wu C
ACS Chem Neurosci; 2021 Jul; 12(14):2629-2642. PubMed ID: 34184869
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines.
Civiello RL; Han X; Beno BR; Chaturvedula PV; Herbst JJ; Xu C; Conway CM; Macor JE; Dubowchik GM
Bioorg Med Chem Lett; 2016 Feb; 26(4):1229-32. PubMed ID: 26832218
[TBL] [Abstract][Full Text] [Related]
57. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.
Luo G; Chen L; Conway CM; Denton R; Keavy D; Signor L; Kostich W; Lentz KA; Santone KS; Schartman R; Browning M; Tong G; Houston JG; Dubowchik GM; Macor JE
J Med Chem; 2012 Dec; 55(23):10644-51. PubMed ID: 23153230
[TBL] [Abstract][Full Text] [Related]
58. Structure-Based Drug Discovery of
Bucknell SJ; Ator MA; Brown AJH; Brown J; Cansfield AD; Cansfield JE; Christopher JA; Congreve M; Cseke G; Deflorian F; Jones CR; Mason JS; O'Brien MA; Ott GR; Pickworth M; Southall SM
J Med Chem; 2020 Jul; 63(14):7906-7920. PubMed ID: 32558564
[TBL] [Abstract][Full Text] [Related]
59. Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.
Buntinx L; Vermeersch S; de Hoon J
Br J Clin Pharmacol; 2015 Nov; 80(5):992-1000. PubMed ID: 26114340
[TBL] [Abstract][Full Text] [Related]
60. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.
Ong JJY; Wei DY; Goadsby PJ
Drugs; 2018 Mar; 78(4):411-437. PubMed ID: 29396834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
